Targeted biotech drugs that attack specific biological molecules that cause disease are bringing new benefitsand fomentingpricing dynamics different from those of traditional drugs.

The ability to make cost-effective exploratory efforts is a powerful enabler of innovation. Unfortunately, drug development is far less conducive to this sort of exploration.

Congress should act in protecting patents for follow-on biologics, relying on a few basic principles that do not suppress research and developmentin this vital sector.

Drug prices have recently become less expensive with the spread of generic versions, but Medicaid support seems to make drugs more expensive.

We need to design regulatory approaches to ensure that molecular diagnostic tests are reliable while not overburdening those seeking to develop these important new technologies.

Follow-on biologics are not like ordinary generics, and therefore require Congress to exercise a deft regulatory hand.

Psychiatry has transformed normal sorrow into depressive disorders due to the uncertainty of the true workings of the brain.